LinKinVax and Inserm Transfert Enter Into an Exclusive Worldwide Licensing Agreement Covering Use of an Innovative Vaccine Platform

LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with Inserm Transfert to develop a vaccine strategy with an innovative mechanism of

Related Keywords

Paris ,France General ,France ,French ,Inserm Universit ,Jacques Auberton Herv ,Inserm Transfert ,Corinne Margot ,Annie Florence Loyer ,Inserm Transfert Initiative ,Mondor Institute For Biomedical Research ,Service Public ,Research Inserm ,Vaccine Research Institute Inserm ,Research Unit ,Vaccine Research Institute ,University Of Paris Est Cr ,Public Service Management Contract ,Baylor Scott White Research Institute ,French National Institute Of The Health ,Dendritic Cells ,Mondor Institute ,Biomedical Research ,Vaccine Research ,Pascale Aug ,Executive Management Board ,Honorary Chairman ,Yves Levy ,French National Institute ,Medical Research ,Florence Loyer ,Linkinvax ,Inserm ,Transfert ,Winter ,Into ,Exclusive ,Orldwide ,Icensing ,Agreement ,Covering ,Nnovative ,Vaccine ,Platform ,